LSD-assisted psychotherapy and the human encounter with death

The authors situate their work in a context of growing clinical interest, historical reflection and limited prior evidence that psychedelics might alter the dying experience. Drawing on literary and anecdotal precedents (notably Aldous Huxley's accounts) and early clinical reports by Kast and Cohen that suggested LSD could reduce pain, anxiety and death-related apprehension in terminal cancer patients, the researchers describe how the Spring Grove and Sinai hospital teams extended their ongoing programme of LSD-assisted psychotherapy to people with terminal cancer. They note that earlier efforts varied in their psychotherapeutic framing and dosage, and that the existing literature was sparse and inconclusive. This paper reports a pilot clinical series in which the authors sought to evaluate whether LSD-assisted psychotherapy, delivered within a preparatory–session–integration psychotherapeutic model, could relieve emotional distress and affect pain-related outcomes in terminal cancer patients. The stated aim was to obtain preliminary data on psychological and analgesic effects, to characterise patients' subjective experiences (including peak or ‘‘mystical’’ experiences), and to identify issues warranting controlled follow-up work.

This was an uncontrolled pilot clinical series of 31 terminal cancer patients treated with LSD-assisted psychotherapy at Spring Grove and Sinai Hospital. Demographics reported for the sample included marital status, race and religion; time since diagnosis varied widely (range 1 month to 13 years, mean about 34 months). The authors note that their overall institutional experience by July 1972 included 60 cancer patients across various projects, but the series described here comprised 31 subjects. The psychotherapeutic procedure comprised three phases: preparatory drug-free psychotherapy (reported preparatory contact totalling typically 6–12 hours, mean close to 9 hours though the extraction contains ambiguous formatting), a single supervised LSD session in hospital (most patients received one session; 28/31 had one session, three patients had additional sessions), and post-session integration interviews over the following week. Family members were involved where appropriate. LSD was usually administered intramuscularly; dose selection was made by the therapist based on psychological defensiveness and body weight and ranged from 200 to 500 micrograms (mode 300 micrograms; reported mean 323 micrograms). During sessions patients wore an eyeshade and headphones and listened to selected classical music; a therapist and a trained psychedelic nurse remained present throughout. Outcome assessment emphasised observer ratings rather than standard psychometric tests, because many patients could not complete instruments such as the POI or MMPI. The team developed a Pahnke–Richards rating instrument yielding scores on a scale of roughly −6 to +6 for clinical domains including depression, psychological isolation, anxiety, difficulty in management, fear of death, preoccupation with pain, and denial. Ratings were obtained one day before and three days after treatment from attending physicians, nurses, family members, LSD therapists/cotherapists and, later, an independent psychiatric social worker. Analgesic use was assessed by converting narcotic regimens to a unified Narcotic Scale of Equivalent Dosages. Data analysis compared pre- and post-treatment scores for each subscale and rater category and also produced pooled global indices (collapsing raters and/or distress categories) to quantify overall change; statistical tests of significance were applied to these pre–post comparisons.

Observer ratings indicated consistent improvement across clinical domains after LSD-assisted psychotherapy. When mean pre- and post-treatment scores were compared across various rater categories and clinical subscales, nearly all between-time differences pointed in a positive direction; of 36 mean-score differences reported, only three did not show statistical significance or a strong positive trend. Many differences were reported as significant at the p<0.001 level. Pooled global indexes for separate categories of emotional and physical distress also showed pre–post differences significant at the p<0.001 level. The authors combined ratings across domains into a single global index per patient and used change on that index to classify outcomes: by their arbitrary thresholds, 9 patients (29.0%) showed “dramatic improvement” (increase ≥4 points), 13 patients (41.9%) had “moderate improvement” (increase 2–4 points), and 9 patients (29.0%) were essentially unchanged (increase <2 points). Two patients had small decreases in their global index (−0.21 and −0.51 points). Analgesic consumption, expressed on the study’s narcotic-equivalent scale, fell from a group mean of 2.58 units pre-treatment to 2.24 units post-treatment. This difference corresponded to a t-score of 1.10 and was not statistically significant. The authors highlight this apparent discrepancy between significant reporter-rated decreases in pain and a nonsignificant change in narcotic use. Most patients received a single LSD session (28/31). The paper presents two detailed case histories illustrating typical therapeutic phenomena: one patient (C-20) experienced a classical ‘‘mystical’’ or peak episode (unity, transcendence of time/space, sacredness, ineffability) with subsequent reduced pain, improved mood and brief return to work before dying about eight months later; another patient (C-29) experienced prolonged processing of loneliness and improved family communication and mood for about two months before symptoms and later decline recurred, with a peaceful death in hospital. The results text and case narratives also note common acute and subacute physical/psychosomatic effects during sessions (nausea, vomiting, tremor, palpitations, fatigue), and that cancer patients frequently reported visions of deceased relatives and more pronounced post-session fatigue than psychiatric patients typically treated with LSD.

The authors interpret the findings as supportive of LSD-assisted psychotherapy’s potential to relieve emotional distress in terminal cancer patients and to alter attitudes toward death. They report that phenomenological material elicited by patients resembled that seen in other patient groups treated with psychedelics (ranging from aesthetic alterations and reliving of childhood memories to archetypal and transcendental experiences). The most dramatic and enduring changes tended to follow intense psychedelic ‘‘peak’’ or mystical experiences; the authors estimate such profound experiences occurred in about 25% of their sample and were associated with marked reductions in fear of death. They discuss the more frequent occurrence of difficult physical symptoms and greater fatigue in cancer patients, noting that some acute somatic reactions during sessions related to the physical illness (for example vomiting with gastrointestinal tumours or incontinence with pelvic tumours). The authors consider mechanisms for the observed analgesic and emotional benefits. They caution that LSD is not a simple or predictable analgesic and suggest psychological mechanisms that may contribute to pain relief, including increased pain tolerance, attentional defocusing from nociceptive loci, and a stronger ‘‘here-and-now’’ orientation reducing anticipatory and memory-related amplification of pain. They also offer potential explanations for the discrepancy between observer-rated pain reduction and minimal change in measured narcotic consumption: concurrent use of other psychoactive medications (not systematically recorded), improved effectiveness of the same narcotic dosages after therapy, and possible habituation or physiological dependence on prolonged narcotic regimens. The authors acknowledge key limitations: this was a pilot, uncontrolled series without a concomitant control group; the constellation and number of raters varied over the study period; many standard psychometric tests could not be completed by ill patients; and the generalisability of findings is limited without controlled replication. They compare their psychotherapy-centred method with prior chemotherapeutic approaches (Kast’s lower-dose, less psychotherapeutic protocol) and conclude that both psychotherapy and pharmacology may contribute to outcomes, but that controlled research is required to disentangle these factors. Practical implications discussed by the authors include potential benefits beyond the patient—improved family communication and bereavement outcomes—and the resource intensity of LSD psychotherapy (long sessions and substantial therapist/nurse time). Because of these demands, they report pursuing shorter-acting agents (e.g. DPT, and possibly MDA or short-acting psilocybin derivatives) that may afford similar therapeutic properties with shorter sessions. The authors emphasise that psychedelic psychotherapy is not ‘‘magic’’ and must be practised with specialist training and supervision; they argue that, when delivered by skilled teams, the procedure appeared relatively safe and promising in this challenging clinical area.